Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arcturus Therapeutics Ltd (ARCT)

Arcturus Therapeutics Ltd (ARCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 187,242
  • Shares Outstanding, K 28,413
  • Annual Sales, $ 152,310 K
  • Annual Income, $ -80,940 K
  • EBIT $ -78 M
  • EBITDA $ -75 M
  • 60-Month Beta 2.10
  • Price/Sales 1.17
  • Price/Cash Flow N/A
  • Price/Book 0.76

Options Overview Details

View History
  • Implied Volatility 94.79% (-21.41%)
  • Historical Volatility 72.00%
  • IV Percentile 55%
  • IV Rank 19.79%
  • IV High 269.02% on 10/21/25
  • IV Low 51.80% on 12/12/24
  • Expected Move (DTE 14) 1.11 (16.30%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 474
  • Volume Avg (30-Day) 571
  • Put/Call OI Ratio 0.51
  • Today's Open Interest 14,151
  • Open Int (30-Day) 57,846
  • Expected Range 5.72 to 7.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.87
  • Number of Estimates 4
  • High Estimate -0.53
  • Low Estimate -1.18
  • Prior Year -1.11
  • Growth Rate Est. (year over year) +21.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.85 +16.75%
on 11/20/25
9.29 -26.48%
on 11/11/25
-2.10 (-23.52%)
since 11/04/25
3-Month
5.85 +16.75%
on 11/20/25
24.17 -71.74%
on 10/21/25
-9.93 (-59.25%)
since 09/04/25
52-Week
5.85 +16.75%
on 11/20/25
24.17 -71.74%
on 10/21/25
-10.39 (-60.34%)
since 12/04/24

Most Recent Stories

More News
Arcturus Therapeutics to Attend Upcoming Investor Conference

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics...

ARCT : 6.83 (+3.64%)
Arcturus Therapeutics: Q3 Earnings Snapshot

Arcturus Therapeutics: Q3 Earnings Snapshot

ARCT : 6.83 (+3.64%)
Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress

Encouraging CF interim Phase 2 data support continued and expanded trial design 12-week safety and preliminary efficacy study in up to 20 CF participants planned to start...

ARCT : 6.83 (+3.64%)
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) and Encourages Investors with Substantial Losses to Contact the Firm

NEWTOWN, Pa. , Nov. 10, 2025 /PRNewswire/ -- Edelson Lechtzin LLP  is investigating potential violations of the federal securities laws involving Arcturus Therapeutics Holdings Inc. ("Arcturus")...

ARCT : 6.83 (+3.64%)
Arcturus Therapeutics to Attend Upcoming Investor Conferences

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics...

ARCT : 6.83 (+3.64%)
2 Stocks to Buy Under $10 That Wall Street Loves

While penny stocks are risky, they also have the potential to deliver outsized gains.

LTRN : 3.77 (+6.50%)
HOTH : 1.1900 (-0.83%)
ARCT : 6.83 (+3.64%)
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics...

ARCT : 6.83 (+3.64%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcturus Therapeutics Holdings Inc. - ARCT

NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Arcturus Therapeutics Holdings Inc.  ("Arcturus" or the "Company") (NASDAQ: ARCT). Such...

ARCT : 6.83 (+3.64%)
Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program

ARCT-032 generally safe and well tolerated Meaningful trends of clinical activity observed via high resolution CT scans After only 28...

ARCT : 6.83 (+3.64%)
Brera Holdings (NASDAQ: BREA) Jumps as ARK Invest Buys $49.7M Stake, Trims Roku and Tempus AI

Brera Holdings (NASDAQ: BREA), which is rebranding as Solmate and pivoting to a Solana-based digital asset treasury and crypto infrastructure, surged after Cathie Wood’s ARK Invest purchased 6,500,001...

ROKU : 94.54 (+1.68%)
BREA : 25.20 (+1.94%)
AVAV : 287.45 (+5.77%)
ATAI : 4.40 (+8.37%)
BIDU : 118.72 (+1.23%)
ARCT : 6.83 (+3.64%)
PONY : 14.60 (+2.96%)

Business Summary

Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated delivery system LUNAR(TM) and UNA Oligomer chemistry technologies. Arcturus Therapeutics Ltd, formerly known as...

See More

Key Turning Points

3rd Resistance Point 7.34
2nd Resistance Point 7.09
1st Resistance Point 6.96
Last Price 6.83
1st Support Level 6.58
2nd Support Level 6.34
3rd Support Level 6.21

See More

52-Week High 24.17
Fibonacci 61.8% 17.17
Fibonacci 50% 15.01
Fibonacci 38.2% 12.85
Last Price 6.83
52-Week Low 5.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar